Zevra Therapeutics (ZVRA) Intangibles (2023 - 2026)

Zevra Therapeutics' Intangibles history runs 4 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• Quarterly Intangibles fell 89.82% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 89.82% YoY) and the FY2025 annual result came in at $6.4 million, down 90.69% from the prior year.
• Intangibles was $6.1 million for Q1 2026 at Zevra Therapeutics, down from $6.4 million in the prior quarter.
• Across five years, Intangibles topped out at $69.2 million in Q4 2023 and bottomed at $2.0 million in Q1 2024.
• A 4-year average of $29.5 million and a median of $6.9 million in 2025 frame the typical range for Intangibles.
• Peak annual rise in Intangibles reached 2900.0% in 2025, while the deepest fall reached 90.69% in 2025.
• Zevra Therapeutics' Intangibles stood at $69.2 million in 2023, then retreated by 0.34% to $69.0 million in 2024, then plunged by 90.69% to $6.4 million in 2025, then decreased by 4.92% to $6.1 million in 2026.
• Business Quant data shows ZVRA's Intangibles at $6.1 million in Q1 2026, $6.4 million in Q4 2025, and $6.7 million in Q3 2025.